Results 171 to 180 of about 2,223,573 (201)

Combined treatment with TNF-α/gefitinib alleviates the resistance to gefitinib in PC-9 cells

Anti-Cancer Drugs, 2009
Gefitinib has been approved for the treatment of patients with non-small cell lung cancer. However, its efficiency is limited by the development of drug resistance. Additional treatments for cases of non-small cell lung cancer relapsing with treatment with gefitinib are urgently required.
Yuan, Ji, Sheng-Lin, Ma, Yi-Ping, Zhang, Juan-Juan, Tang, Yan-Ming, Wu, Yan-Jun, Lu   +5 more
openaire   +2 more sources

Gefitinib reverses breast cancer resistance protein–mediated drug resistance

Molecular Cancer Therapeutics, 2004
AbstractBreast cancer resistance protein (BCRP) is an ATP binding cassette transporter that confers resistance to a series of anticancer agents such as 7-ethyl-10-hydroxycamptothecin (SN-38), topotecan, and mitoxantrone. In this study, we evaluated the possible interaction of gefitinib, a selective epidermal growth factor receptor tyrosine kinase ...
Kae, Yanase, Satomi, Tsukahara, Sakiyo, Asada, Etsuko, Ishikawa, Yasuo, Imai, Yoshikazu, Sugimoto   +5 more
openaire   +2 more sources

Inhibition of autophagy by YC-1 promotes gefitinib induced apoptosis by targeting FOXO1 in gefitinib-resistant NSCLC cells

European Journal of Pharmacology, 2021
Non-small cell lung cancer (NSCLC) is the most common cancer in the world. Gefitinib, an inhibitor of EGFR tyrosine kinase, is highly effective in treating NSCLC patients with activating EGFR mutations (L858R or Ex19del). However, despite excellent disease control with gefitinib therapy, innate resistance and inevitable acquired resistance represent ...
Hui, Hu, Xiao-Wei, Zhang, Lin, Li, Ming-Ning, Hu, Wen-Qian, Hu, Jing-Ying, Zhang, Xiao-Kang, Miao, Wen-Le, Yang, Ling-Yun, Mou   +8 more
openaire   +2 more sources

Gefitinib Reverses Chemotherapy Resistance in Gefitinib-Insensitive Multidrug Resistant Cancer Cells Expressing ATP-Binding Cassette Family Protein

Cancer Research, 2005
Abstract Gefitinib inhibits the ATP-binding site of the tyrosine kinase associated with the epidermal growth factor receptor. It is conceivable that gefitinib may inhibit functions of ATP-binding cassette (ABC) transporters by binding at their ATP-binding sites.
Chih-Hsin, Yang, Ching-Ju, Huang, Chao-Shun, Yang, Yu-Chuan, Chu, Ann-Lii, Cheng, Jacqueline, Whang-Peng, Pan-Chyr, Yang   +6 more
openaire   +2 more sources

Effect of sequential chemotherapy and gefitinib on survival outcome in advanced NSCLC with acquired gefitinib resistance.

Journal of Clinical Oncology, 2013
e19085 Background: As one of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), gefitinib has been proven to be highly effective for patients with advanced NSCLC. However, almost all patients who experienced remarkable improvement eventually develop acquired resistance. There are no approved therapies after disease progression
Wang Huijuan, Zhang Mina, Zhang guo Wei, Zhu Hui, Wang Qiming, Li Peng, Yan Xiangtao, Li Shaomei, Ma Zhi Yong   +8 more
openaire   +1 more source

Inhibitor of ghrelin receptor reverses gefitinib resistance in lung cancer

Human Cell, 2019
Gefitinib is the first-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), which is used in the treatment of NCSLC patients through interrupting EGFR signaling pathway. Although gefitinib prolongs patients' progression-free survival (PFS), acquired resistance occurs in advanced NSCLC patients.
Xiaoyou, Li, Xia, Zhao, Chenchen, Li, Siwen, Liu, Fei, Yan, Yue, Teng, Jifeng, Feng, Dengshun, Miao   +7 more
openaire   +2 more sources

Gefitinib derivatives and drug-resistance: A perspective from molecular dynamics simulations

Computers in Biology and Medicine, 2023
Epidermal-growth factor receptor (EGFR) is a transmembrane tyrosine kinase (TK) with a significant role in cell survival. EGFR is upregulated in various cancer cells and known as a druggable target. Gefitinib is a first-line TK inhibitor used against metastatic non-small cell lung cancer (NSCLC).
A. Ahmadi, E. Mohammadnejadi, Nima Razzaghi-Asl   +2 more
openaire   +3 more sources

Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer [PDF]

Cell Death and Disease, 2014
The involvement of Axl kinase in non-small cell lung cancer's (NSCLC) acquired resistance to tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib has been identified recently, but the mechanism by which Axl contributes to TKI resistance is largely unknown.
Wang, Y, Xia, H, Zhuang, Z, Miao, L, Chen, X, Cai, H   +5 more
exaly   +3 more sources

Aucklandia lappa DC. extract enhances gefitinib efficacy in gefitinib-resistance secondary epidermal growth factor receptor mutations

Journal of Ethnopharmacology, 2017
Aucklandia lappa DC. is a widely used medicinal plant in China, India and Pakistan for a long time. Previously, a number of different pharmacological experiments in vitro and in vivo have convincingly demonstrated the abilities of it to exhibit anticancer activities. Reynoutria japonica Houtt.
Guan, Huang, Yanli, Tong, Qidi, He, Jie, Wang, Zuanguang, Chen   +4 more
openaire   +2 more sources

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours

Lung Cancer, 2008
For patients with advanced non-small cell lung cancer (NSCLC), the introduction of the epi- dermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, into clinical practice was promising. Treatment with either of these agents is associated with an objective response in 10-20% of patients.
openaire   +2 more sources